Phase 2 N=30 Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.
Impaired Glucose Tolerance
Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 Incretins in Impaired Fasting Glucose
Pre-diabetes
Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05
N/A N=26 Incretin Effect in People With Impaired Fasting Glucose
Obesity
Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min
N/A N=70 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Impaired Glucose Tolerance · Prediabetic State
Primary: AIM 1: Change in Flow Mediated Dilation (FMD) (%) — -0.0012; 0.018; 0.014; 0.0053 percentage of arterial dilation change — p=0.943
N/A N=21 Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth
Obesity · Impaired Glucose Tolerance · Type 2 Diabetes Mellitus
Primary: Mean Percent Change From Baseline in Whole-body Insulin Sensitivity — 87.4; 63.1 percentage of change from baseline
N/A N=56 Effect of Dietary Glycemic Index on Beta-cell Function
Impaired Glucose Tolerance · Oxidative Stress · Prediabetes
Primary: Disposition Index — 708; 793; 791 unitless
N/A N=35 Insulin Sensitivity, Impaired Counterregulation, and Glucose Variability
Type 1 Diabetes Mellitus
Primary: Insulin Sensitivity — 3.37*10^-4 1/min per uU/mL
Phase 3 N=602 Actos Now for Prevention of Diabetes (ACT NOW)
Impaired Glucose Tolerance · Type 2 Diabetes
Primary: Prevention of Type 2 Diabetes — 16.1; 5.0 percentage of participants
N/A N=1,939 Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care
Type 2 Diabetes Mellitus · Prediabetic State
Primary: Ability of Different Screening Tests Which Can be Performed Opportunistically (During Outpatient Visits -- at Any Time of Day, Regardless of Meal Status) to Predict…
N/A N=39 Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Prediabetic State
Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…
Phase 2 N=91 A Study to Determine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy Subjects
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790
N/A N=28 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Phase 2 N=12 The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Insulin Secretion — 56766 pmol/l * 90 minutes
Phase 3 N=202 Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test). — 9.27; 9.11; 7.28; 8.32 mmol/L — p=0.0028
Phase 4 N=24 Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes
Prediabetes · Impaired Fasting Glucose · Impaired Glucose Tolerance
Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005
N/A N=38 Pilot Study of Resveratrol in Older Adults With Impaired Glucose Tolerance
Impaired Glucose Tolerance
Primary: Post Meal Glucose Area Under the Curve — 508; 513 mg*hr/dL
Phase 3 N=21 Study to Evaluate the Effects of Colesevelam on Insulin Sensitivity and ß-Cell Function in Subjects With Impaired Fasting Glucose (Prediabetes)
Impaired Fasting Glucose · Prediabetes
Primary: Acute Insulin Response (AIRg) to Intravenous Glucose — 1866; 1752 pmol/1*min
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
N/A N=44 Effect of Fermentable Carbohydrate on Glucose Homeostasis
Prediabetes
Primary: Glycaemic Control — -0.23; 0.44 mmol//l — p=0.005
Phase 2 N=57 Correlation of Continuous Glucose Monitoring and Glucose Tolerance Testing With Pregnancy Outcomes
Diabetes, Gestational
Primary: Correlation Between Glucose AUC and Birth Weight. — 0.2902; 0.2935; 0.2915; 0.2859 correlation coefficient — p=0.035
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
Phase 1 N=27 A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED)
The Methodology Assessment of Glucose Dependent Insulin Secretion
Primary: Change From Baseline in Insulin Secretion Rate (ISR) Normalized to Ambient Plasma Glucose — 2.14; 1.49; 0.53; 2.95 (ng/min) / (mg/dL) — p=<0.001
N/A N=24 Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion
Glucose Intolerance
Primary: Postprandial Glucose Levels at Week 12 — 9.5; 9.9 mmol/L — p=0.380
Phase 1 N=36 Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)
Hypertension
Primary: Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT) — 3.44; 3.55 ng/minute — p=0.067
N/A N=200 Fasting Versus Fed: Effect of Oral Intake Prior to the Glucose Tolerance Test in Pregnancy
Gestational Diabetes · Diagnoses Disease · Pregnancy in Diabetic
Primary: Number of Participants With a Positive Gestational Diabetes Mellitus (GDM) Screen (>= 140 mg/dL) on the 1 Hour 50-g Oral Glucose Tolerance Test (OGTT) — 31; 13…
N/A N=163 IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
Type 2 Diabetes
Primary: Difference in Change in 14-day CGM-derived TIR From (3 Months Minus Baseline) — 28; 22 percentage of time with glucose 70-180 m
N/A N=12 Glycemic Response Testing
Glycemic Index · Glycemic Response
Primary: Glycemic Response Measured as the Positive Incremental Area Under the Time-concentration Curve(iAUC) Calculated From Individual Glucose Measurements Upon Consumption of…
N/A N=43 The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
Adult Growth Hormone Deficiency · Hypothalamic-pituitary Disorders
Primary: Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD). — 0.9; 0.6; 0.7 ng/mL
Phase 4 N=59 Application and Effectiveness Analysis of Internet-based Diabetes Prevention Program
Type 2 Diabetes
Primary: Incidence of Type 2 Diabetes Mellitus — 1; 1 participants